Cargando…

Long-Term Weight Change after Initiating Second-Generation Antidepressants

(1) Objective: To examine the relationship between the choice of second-generation antidepressant drug treatment and long-term weight change; (2) Methods: We conducted a retrospective cohort study to investigate the relationship between choice of antidepressant medication and weight change at two ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Arterburn, David, Sofer, Tamar, Boudreau, Denise M., Bogart, Andy, Westbrook, Emily O., Theis, Mary Kay, Simon, Greg, Haneuse, Sebastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850471/
https://www.ncbi.nlm.nih.gov/pubmed/27089374
http://dx.doi.org/10.3390/jcm5040048
_version_ 1782429670265847808
author Arterburn, David
Sofer, Tamar
Boudreau, Denise M.
Bogart, Andy
Westbrook, Emily O.
Theis, Mary Kay
Simon, Greg
Haneuse, Sebastien
author_facet Arterburn, David
Sofer, Tamar
Boudreau, Denise M.
Bogart, Andy
Westbrook, Emily O.
Theis, Mary Kay
Simon, Greg
Haneuse, Sebastien
author_sort Arterburn, David
collection PubMed
description (1) Objective: To examine the relationship between the choice of second-generation antidepressant drug treatment and long-term weight change; (2) Methods: We conducted a retrospective cohort study to investigate the relationship between choice of antidepressant medication and weight change at two years among adult patients with a new antidepressant treatment episode between January, 2006 and October, 2009 in a large health system in Washington State. Medication use, encounters, diagnoses, height, and weight were collected from electronic databases. We modeled change in weight and BMI at two years after initiation of treatment using inverse probability weighted linear regression models that adjusted for potential confounders. Fluoxetine was the reference treatment; (3) Results: In intent-to-treat analyses, non-smokers who initiated bupropion treatment on average lost 7.1 lbs compared to fluoxetine users who were non-smokers (95% CI: −11.3, −2.8; p-value < 0.01); smokers who initiated bupropion treatment gained on average 2.2 lbs compared to fluoxetine users who were smokers (95% CI: −2.3, 6.8; p-value = 0.33). Changes in weight associated with all other antidepressant medications were not significantly different than fluoxetine, except for sertraline users, who gained an average of 5.9 lbs compared to fluoxetine users (95% CI: 0.8, 10.9; p-value = 0.02); (4) Conclusion: Antidepressant drug therapy is significantly associated with long-term weight change at two years. Bupropion may be considered as the first-line drug of choice for overweight and obese patients unless there are other existing contraindications.
format Online
Article
Text
id pubmed-4850471
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-48504712016-05-03 Long-Term Weight Change after Initiating Second-Generation Antidepressants Arterburn, David Sofer, Tamar Boudreau, Denise M. Bogart, Andy Westbrook, Emily O. Theis, Mary Kay Simon, Greg Haneuse, Sebastien J Clin Med Article (1) Objective: To examine the relationship between the choice of second-generation antidepressant drug treatment and long-term weight change; (2) Methods: We conducted a retrospective cohort study to investigate the relationship between choice of antidepressant medication and weight change at two years among adult patients with a new antidepressant treatment episode between January, 2006 and October, 2009 in a large health system in Washington State. Medication use, encounters, diagnoses, height, and weight were collected from electronic databases. We modeled change in weight and BMI at two years after initiation of treatment using inverse probability weighted linear regression models that adjusted for potential confounders. Fluoxetine was the reference treatment; (3) Results: In intent-to-treat analyses, non-smokers who initiated bupropion treatment on average lost 7.1 lbs compared to fluoxetine users who were non-smokers (95% CI: −11.3, −2.8; p-value < 0.01); smokers who initiated bupropion treatment gained on average 2.2 lbs compared to fluoxetine users who were smokers (95% CI: −2.3, 6.8; p-value = 0.33). Changes in weight associated with all other antidepressant medications were not significantly different than fluoxetine, except for sertraline users, who gained an average of 5.9 lbs compared to fluoxetine users (95% CI: 0.8, 10.9; p-value = 0.02); (4) Conclusion: Antidepressant drug therapy is significantly associated with long-term weight change at two years. Bupropion may be considered as the first-line drug of choice for overweight and obese patients unless there are other existing contraindications. MDPI 2016-04-13 /pmc/articles/PMC4850471/ /pubmed/27089374 http://dx.doi.org/10.3390/jcm5040048 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Arterburn, David
Sofer, Tamar
Boudreau, Denise M.
Bogart, Andy
Westbrook, Emily O.
Theis, Mary Kay
Simon, Greg
Haneuse, Sebastien
Long-Term Weight Change after Initiating Second-Generation Antidepressants
title Long-Term Weight Change after Initiating Second-Generation Antidepressants
title_full Long-Term Weight Change after Initiating Second-Generation Antidepressants
title_fullStr Long-Term Weight Change after Initiating Second-Generation Antidepressants
title_full_unstemmed Long-Term Weight Change after Initiating Second-Generation Antidepressants
title_short Long-Term Weight Change after Initiating Second-Generation Antidepressants
title_sort long-term weight change after initiating second-generation antidepressants
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850471/
https://www.ncbi.nlm.nih.gov/pubmed/27089374
http://dx.doi.org/10.3390/jcm5040048
work_keys_str_mv AT arterburndavid longtermweightchangeafterinitiatingsecondgenerationantidepressants
AT sofertamar longtermweightchangeafterinitiatingsecondgenerationantidepressants
AT boudreaudenisem longtermweightchangeafterinitiatingsecondgenerationantidepressants
AT bogartandy longtermweightchangeafterinitiatingsecondgenerationantidepressants
AT westbrookemilyo longtermweightchangeafterinitiatingsecondgenerationantidepressants
AT theismarykay longtermweightchangeafterinitiatingsecondgenerationantidepressants
AT simongreg longtermweightchangeafterinitiatingsecondgenerationantidepressants
AT haneusesebastien longtermweightchangeafterinitiatingsecondgenerationantidepressants